Medical Affairs Reputations (EU5) [Melanoma]
Find out what the leading team gets right, and what the trailing team gets wrong
The medical affairs team for a leading melanoma treatment is doing all the right things in the EU5 countries. Oncologists gave it the highest overall score and the highest performance and satisfaction ratings on most medical affairs services. Meanwhile, a rival team has done just the opposite, earning the lowest scores across the board. This report reveals how your team compares, so you can learn from those successes and failures, and build better relationships with doctors.
Comparing 7 major melanoma treatments from Amgen, Bristol-Myers Squibb, Merck Sharp & Dohme, Novartis, and Roche, this report reveals:
Find out what more doctors want from your medical affairs team including
Top Takeaways
Developed with the help of medical affairs specialists, this report gives you an in-depth comparison of 7 medical affairs teams—answering important questions like:
What do doctors need?
We surveyed 150 medical oncologists and dermato-oncologists from the EU5 (France, Italy, Germany, Spain, UK)—chosen from the largest community of validated physicians in the world.
All respondents:
MONEY BACK GUARANTEE!
At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.
About FirstWord
FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.
FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.
FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.
The medical affairs team for a leading melanoma treatment is doing all the right things in the EU5 countries. Oncologists gave it the highest overall score and the highest performance and satisfaction ratings on most medical affairs services. Meanwhile, a rival team has done just the opposite, earning the lowest scores across the board. This report reveals how your team compares, so you can learn from those successes and failures, and build better relationships with doctors.
Comparing 7 major melanoma treatments from Amgen, Bristol-Myers Squibb, Merck Sharp & Dohme, Novartis, and Roche, this report reveals:
Find out what more doctors want from your medical affairs team including
- How doctors rate your team overall, and on 12 key medical affairs services.
- Which medical affairs services are most important, and what you can do to improve them.
- How, and how often doctors want to meet with your team.
Top Takeaways
- The right stuff: The team that earns the highest overall quality score also gets the highest performance and satisfaction scores for most medical affairs services.
- Meanwhile, at the bottom of the pack: The team that earns the lowest overall score also trails the pack in performance and satisfaction scores for most medical affairs services.
- Doctors are hungry for information: They identified 4 ways teams can improve information provision, and highlighted at least 1 specific type of information they want more of.
- Four teams need specific improvements: They each need to improve at least one medical affairs service. Find out which one.
- Calls for a better attitude: Over 20% of surveyed doctors said teams needed a better medical affairs attitude, and pointed to specific improvements.
- Dialling in the frequency: Some teams are reaching out to doctors as often as doctors would like. Others need to reach out more often or back off a bit.
- Imlygic (talimogene laherparepvec; Amgen)
- Keytruda (pembrolizumab; Merck Sharp & Dohme)
- Mekinist (trametinib; Novartis)
- Opdivo (nivolumab; Bristol-Myers Squibb)
- Tafinlar (dabrafenib; Novartis)
- Yervoy (ipilimumab; Bristol-Myers Squibb)
- Zelboraf (vemurafenib; Roche)
Developed with the help of medical affairs specialists, this report gives you an in-depth comparison of 7 medical affairs teams—answering important questions like:
What do doctors need?
- How, and how often are they using your medical affairs team?
- What services do they consider most important?
- How often should you contact them? What channels are best?
- How memorable are your team’s interactions with doctors?
- How do doctors rank your team for performance and satisfaction in 12 key areas?
- How does your team compare to the competition—in each area, and overall?
- Are you delivering the services that are most important to doctors?
- Where do you need to improve?
- How can your team enhance its services?
We surveyed 150 medical oncologists and dermato-oncologists from the EU5 (France, Italy, Germany, Spain, UK)—chosen from the largest community of validated physicians in the world.
All respondents:
- Have been practicing for between 3 and 35 years
- See at least 5 patients with melanoma in a typical month
- Devote at least 50% of their time to direct patient care
- Have interacted with at least one listed product’s medical affairs team in the past 6 months.
MONEY BACK GUARANTEE!
At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.
About FirstWord
FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.
FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.
FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.
1. OBJECTIVES, SURVEY METHODOLOGY AND SAMPLING, PRODUCTS INCLUDED IN THE SURVEY, EXECUTIVE SUMMARY
2. CURRENT STATUS OF INTERACTIONS WITH DIFFERENT MEDICAL AFFAIRS TEAMS
2.1 Interactions in the past 6 months with Medical Affairs teams for each product
2.2 Current frequency of interactions with medical affair teams for each product
3. COMPETITIVE EVALUATION OF MEDICAL AFFAIRS TEAMS PERFORMANCE ON VARIOUS ATTRIBUTES
3.1 Evaluation of overall quality of interactions with Medical Affairs teams for each product
3.2 Attribute importance of Medical Affairs teams roles to physicians’ practice
3.3 EdgeMap analysis – Competitive evaluation on Medical Affairs teams performance on attributes
3.4 Competitive evaluation of physicians satisfaction of interaction with Medical Affairs teams
3.5 Need-Gap analysis by product
4. PREFERRED INTERACTION MEDIA, FREQUENCY, AND SUGGESTIONS FOR IMPROVEMENT
4.1 Preferred interaction media and frequency, and suggestions for improvement
5. APPENDIX
2. CURRENT STATUS OF INTERACTIONS WITH DIFFERENT MEDICAL AFFAIRS TEAMS
2.1 Interactions in the past 6 months with Medical Affairs teams for each product
2.2 Current frequency of interactions with medical affair teams for each product
3. COMPETITIVE EVALUATION OF MEDICAL AFFAIRS TEAMS PERFORMANCE ON VARIOUS ATTRIBUTES
3.1 Evaluation of overall quality of interactions with Medical Affairs teams for each product
3.2 Attribute importance of Medical Affairs teams roles to physicians’ practice
3.3 EdgeMap analysis – Competitive evaluation on Medical Affairs teams performance on attributes
3.4 Competitive evaluation of physicians satisfaction of interaction with Medical Affairs teams
3.5 Need-Gap analysis by product
4. PREFERRED INTERACTION MEDIA, FREQUENCY, AND SUGGESTIONS FOR IMPROVEMENT
4.1 Preferred interaction media and frequency, and suggestions for improvement
5. APPENDIX
